BioMedomics develops point-of-care (POC) clinical diagnostics with a focus on immunologically-based disease-specific tests and the advanced quantitative POC platforms utilized in personalized medicine molecular diagnostics. The firm markets these assays & technologies to corporate strategic partners who take them to the end-customer market. Biomedomics products includes deoxyribonucleic acid research reagents; human, mouse, and rat genepool products; tissue array products; and antibodies. Designing and developing real-time cell electronic sensing technology for analyzing cell-based assay procedures, the company also offers contract assay services such as cell proliferation, cytotoxicity, adhesion, viability, and invasion.
